Gregory W. Mattingly

Washington University School of Medicine

H指数:21

被引数:2,457

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinically Meaningful Within-Patient Change in Core Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents Treated With Centanafadine: Results From Two Phase 3 Randomized Clinical Trials

临床上有意义的经Centanafadine治疗儿童和青少年核心注意缺陷/多动障碍症状的组内变化：来自两项III期随机临床试验的结果

Journal of Attention Disorders

IF2.2

2026-09-230

PRE

Vortioxetine in treatment of depression with somatic comorbidities in routine practice: sub-group analysis of the RELIEVE study

沃瑞酮在伴有躯体合并症的抑郁症治疗中的常规实践：RELIEVE研究的亚组分析

Journal of Affective Disorders

IF4.9

2025-11-160

OAAI

Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis

帕利哌酮 palmitate 6个月治疗在精神分裂症中的长期症状和功能缓解：一项为期3年的事后分析

Neuropsychiatric Disease and Treatment

IF2.9

2025-06-180

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial

CNS SPECTRUMS

IF4.1

2025-01-170

PRE

Reply: the inclusion of methylphenidate in the WHO list of essential medicines is endorsed by millions of people with ADHD

EUROPEAN CHILD & ADOLESCENT PSYCHIATRY

IF4.9

2024-08-280

PRE

Long-term safety and frequency of repeat zuranolone treatment in patients with major depressive disorder rolling over from the randomised CORAL Study into the open-label SHORELINE Study

EUROPEAN PSYCHIATRY

IF6.7

2024-08-270

OAAI

AACAP Endorses the Inclusion of Methylphenidate in the WHO Model Lists of Essential Medicines

AACAP赞同将哌醋甲酯纳入世卫组织基本药物标准清单

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY

IF9.5

2024-07-011

PRE

Expert consensus statement for telepsychiatry and attention-deficit hyperactivity disorder

CNS SPECTRUMS

IF4.1

2024-05-205

PRE

ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines

EUROPEAN CHILD & ADOLESCENT PSYCHIATRY

IF4.9

2024-04-251

PRE

Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents

EXPERT REVIEW OF NEUROTHERAPEUTICS

IF3.4

2024-03-191

RECENT UPDATES IN ADHD DIGITAL CARE

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY

IF9.5

2023-10-010

PRE

Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder

了解神经活性类固醇和gaba能化合物在重度抑郁症中的作用机制和临床效果

TRANSLATIONAL PSYCHIATRY

IF6.2

2023-06-2651

OAAI

Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder

FRONTIERS IN PSYCHIATRY

IF3.2

2023-06-230

OAAI

Population Pharmacokinetic-Pharmacodynamic Modeling of Variable Wear Times for a Dextroamphetamine Transdermal System

CNS SPECTRUMS

IF4.1

2023-04-141

Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study

在现实世界的临床实践中，沃替西汀对重度抑郁症的有效性: 全球reval研究的美国队列结果

FRONTIERS IN PSYCHIATRY

IF3.2

2023-01-046

OAAI

POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF VARIABLE WEAR TIMES FOR A DEXTROAMPHETAMINE TRANSDERMAL SYSTEM

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY

IF9.5

2022-10-010

PRE

Assessing the educational needs of physicians in the management of patients with Tourette syndrome: results of a United States survey on practicing clinicians and caregivers (Feb, 10.1017/S1092852921000766, 2022)

CNS SPECTRUMS

IF4.1

2022-07-061

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

在现实世界的临床实践中，沃替西汀对重度抑郁症患者的有效性: reval研究的结果

FRONTIERS IN PSYCHIATRY

IF3.2

2022-03-0924

OAAI

Assessing the educational needs of physicians in the management of patients with Tourette syndrome: results of a United States survey on practicing clinicians and caregivers

CNS SPECTRUMS

IF4.1

2022-02-184

PRE

Vortioxetine in routine clinical practice: results from the real-life effectiveness of vortioxetine (RELIEVE) study

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2021-12-012

PRE

Gregory W. Mattingly

个人简介

教育背景

工作经历

荣誉奖项

研究方向